Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease

被引:48
|
作者
Martin, JL [1 ]
Begun, J [1 ]
Schindeler, A [1 ]
Wickramasinghe, WA [1 ]
Alewood, D [1 ]
Alewood, PF [1 ]
Bergman, DA [1 ]
Brinkworth, RI [1 ]
Abbenante, G [1 ]
March, DR [1 ]
Reid, RC [1 ]
Fairlie, DP [1 ]
机构
[1] Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia
关键词
D O I
10.1021/bi990174x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High-resolution crystal structures are described for seven macrocycles complexed with HIV-1 protease (HIVPR). The macrocycles possess two amides and an aromatic group within 15-17 membered rings designed to replace N- or C-terminal tripeptides from peptidic inhibitors of HIVPR. Appended to each macrocycle is a transition state isostere and either an acyclic peptide, nonpeptide, or another macrocycle. These cyclic analogues are potent inhibitors of HIVPR, and the crystal structures show them to be structural mimics of acyclic peptides, binding in the active site of HIVPR via the same interactions. Each macrocycle is restrained to adopt a P-strand conformation which is preorganized for protease binding. An unusual feature of the binding of C-terminal macrocyclic inhibitors is the interaction between a positively charged secondary amine and a catalytic aspartate of HIVPR. A bicyclic inhibitor binds similarly through its secondary amine that lies between its component N-terminal and C-terminal macrocycles. In contrast, the corresponding tertiary amine of the N-terminal macrocycles does not interact with the catalytic aspartates. The amine-aspartate interaction induces a 1.5 Angstrom N-terminal translation of the inhibitors in the active site and is accompanied by weakened interactions with a water molecule that bridges the ligand to the enzyme, as well as static disorder in enzyme flap residues. This flexibility may facilitate peptide cleavage and product dissociation during catalysis. Proteases [Aba(67,95)]HIVPR and [Lys(7),Ile(33),Aba(67,95)]- HIVPR used in this work were shown to have very similar crystal structures.
引用
收藏
页码:7978 / 7988
页数:11
相关论文
共 50 条
  • [41] NOVEL PSEUDOSYMMETRIC INHIBITORS OF HIV-1 PROTEASE
    FASSLER, A
    ROSEL, J
    GRUTTER, M
    TINTELNOTBLOMLEY, M
    ALTERI, E
    BOLD, G
    LANG, M
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1993, 3 (12) : 2837 - 2842
  • [42] Fat accumulation and HIV-1 protease inhibitors
    Stricker, RB
    Goldberg, B
    LANCET, 1998, 352 (9137): : 1392 - 1392
  • [43] The Triple Threat of HIV-1 Protease Inhibitors
    Potempa, Marc
    Lee, Sook-Kyung
    Wolfenden, Richard
    Swanstrom, Ronald
    FUTURE OF HIV-1 THERAPEUTICS: RESISTANCE IS FUTILE?, 2015, 389 : 203 - 241
  • [44] HIV-1 protease inhibitors and drug interactions
    Welch, S
    ADDICTION, 1997, 92 (07) : 905 - 905
  • [45] NONPEPTIDE COMPETITIVE INHIBITORS OF HIV-1 PROTEASE
    TUMMINO, PJ
    FERGUSON, D
    HUPE, L
    TAIT, B
    HUPE, D
    FASEB JOURNAL, 1994, 8 (07): : A1373 - A1373
  • [46] Conformational analysis of HIV-1 protease inhibitors
    Brown, Jeanice
    Parish, Carol A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 52 - 52
  • [47] Lipopeptides as dimerization inhibitors of HIV-1 protease
    Schramm, HJ
    de Rosny, E
    Reboud-Ravaux, M
    Büttner, J
    Dick, A
    Schramm, W
    BIOLOGICAL CHEMISTRY, 1999, 380 (05) : 593 - 596
  • [48] HIV-1 protease inhibitors - A review for clinicians
    Deeks, SG
    Smith, M
    Holodniy, M
    Kahn, JO
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02): : 145 - 153
  • [49] Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors
    Calugi, Chiara
    Guarna, Antonio
    Trabocchi, Andrea
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 84 : 444 - 453
  • [50] Steroids as possible inhibitors of HIV-1 protease
    Schramm, HJ
    Quéré, L
    Büttner, J
    Wenger, T
    Dick, A
    Schramm, W
    AIDS, 1998, 12 (06) : 682 - 685